Clementine Levy, Guillaume Lassailly, Erika Parmentier, Thibault Duburcq, Philippe Mathurin, Julien Poissy
The American journal of gastroenterology 2020 OctWe investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus. This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group. Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%). Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.
Clementine Levy, Guillaume Lassailly, Erika Parmentier, Thibault Duburcq, Philippe Mathurin, Julien Poissy. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice. The American journal of gastroenterology. 2020 Oct;115(10):1716-1718
PMID: 32858566
View Full Text